Table 1.
Clinicopathological characteristics by cancer type (n = 88)
| Characteristics | Colorectal cancer n (%) |
Gastric cancer n (%) |
Esophageal cancer n (%) | P value |
|---|---|---|---|---|
| Sex | ||||
| Male | 36 (45) | 2 (40) | 3 (100) | 0.195 |
| Female | 44 (55) | 3 (60) | 0 (0) | |
| Median age (min-max) | 54 (27-80) | 58 (46-73) | 72 (60-77) | 0.149 |
| Cancer stagea | ||||
| Stage I | 8 (10) | 0 (0) | 0 (0) | 0.453 |
| Stage II | 22 (27.5) | 2 (40) | 3 (60) | |
| Stage III | 28 (35) | 3 (60) | 1 (20) | |
| Stage IV | 22 (27.5) | 0 (0) | 1 (20) | |
| Treatment status at first ctDNA test | ||||
| Chemotherapy/immunotherapy | 21 (26.3) | 0 (0) | 2 (40) | 0.268 |
| Post-surgery | 20 (25) | 1 (33.3) | 1 (20) | |
| Pre-surgery | 11 (13.8) | 2 (66.7) | 1 (20) | |
| Surveillance | 28 (35) | 0 (0) | 1 (20) |
a
Staging at baseline based on the American Joint Committee on Cancer (AJCC) TNM (tumor–node–metastasis) staging system.